Largest biotech by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Amgen leads the 24 biotech ranked by total liabilities, at NOK 793.7B, ahead of Gilead Sciences (NOK 352.7B) and Biogen (NOK 108.3B). Figures as of 18 Nov 2026, 14:30 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- AmgenNOK 793.7B
- Median
- NOK 6.8B
- Combined market value
- NOK 8.21T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AmgenAMGN · Health Care | NOK 793.7B | NOK 2.38T | NOK 4,393.77 | 0.96% down | 34% up | ||
| 2 | Gilead SciencesGILD · Health Care | NOK 352.7B | NOK 2.05T | NOK 1,649.49 | 1.60% up | 33% up | ||
| 3 | BiogenBIIB · Health Care | NOK 108.3B | NOK 359.2B | NOK 2,429.67 | 0.34% down | 49% up | ||
| 4 | ModernaMRNA · Health Care | NOK 35.7B | NOK 815.4B | NOK 2,015.11 | 0.58% up | 755% up | ||
| 5 | BioNTechBNTX · Health Care | NOK 29.7B | NOK 203.8B | NOK 822.13 | 0.47% down | 16% down | ||
| 6 | QiagenQGEN · Health Care | NOK 24.2B | NOK 99.4B | NOK 481.30 | 0.14% down | 12% up | ||
| 7 | Halozyme TherapeuticsHALO · Health Care | NOK 24B | NOK 106B | NOK 929.76 | 0.55% down | 37% up | ||
| 8 | Neurocrine BiosciencesNBIX · Health Care | NOK 13.4B | NOK 162.7B | NOK 1,607.44 | 0.37% up | 20% up | ||
| 9 | argenxARGX · Health Care | NOK 13.2B | NOK 577.3B | NOK 9,179.62 | 0.36% down | 4% up | ||
| 10 | ImmunityBioIBRX · Health Care | NOK 9.7B | NOK 64.4B | NOK 60.53 | 0.20% down | 193% up | ||
| 11 | RepligenRGEN · Health Care | NOK 8.2B | NOK 100.4B | NOK 1,571.21 | 0.37% down | 5% up | ||
| 12 | Revolution MedicinesRVMD · Health Care | NOK 7B | NOK 340.9B | NOK 1,576.15 | 2.50% down | 131% up | ||
| 13 | ExelixisEXEL · Health Care | NOK 6.6B | NOK 160.9B | NOK 659.56 | 0.61% down | 63% up | ||
| 14 | Bio-TechneTECH · Health Care | NOK 4.6B | NOK 110.5B | NOK 703.64 | 0.22% down | 26% up | ||
| 15 | CRISPR TherapeuticsCRSP · Health Care | NOK 3.3B | NOK 37.7B | NOK 388.98 | 0.54% down | 21% down | ||
| 16 | VaxcytePCVX · Health Care | NOK 3.1B | NOK 91.1B | NOK 575.47 | 3.59% down | 22% up | ||
| 17 | Adaptive BiotechnologiesADPT · Health Care | NOK 2.8B | NOK 43.3B | NOK 267.58 | 3.05% down | 88% up | ||
| 18 | Kodiak SciencesKOD · Health Care | NOK 1.9B | NOK 61.3B | NOK 937.80 | 3.90% down | 396% up | ||
| 19 | Twist BioscienceTWST · Health Care | NOK 1.6B | NOK 74B | NOK 1,085.06 | 6.63% up | 340% up | ||
| 20 | Kymera TherapeuticsKYMR · Health Care | NOK 1.6B | NOK 100.5B | NOK 1,177.29 | 3.44% down | 87% up | ||
| 21 | Scholar Rock HoldingSRRK · Health Care | NOK 1.5B | NOK 53.3B | NOK 436.74 | 1.21% up | 14% up | ||
| 22 | Krystal BiotechKRYS · Health Care | NOK 1.1B | NOK 85.4B | NOK 2,883.16 | 0.32% down | 46% up | ||
| 23 | ImmunovantIMVT · Health Care | NOK 1B | NOK 66.6B | NOK 321.74 | 0.21% down | 43% up | ||
| 24 | CG OncologyCGON · Health Care | NOK 377.7M | NOK 68.3B | NOK 764.77 | 6.89% down | 85% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6881 NOK).
Questions and answers
Which biotech rank first by total liabilities?
Amgen (NOK 793.7B), Gilead Sciences (NOK 352.7B) and Biogen (NOK 108.3B) are the top three of the 24 biotech ranked by total liabilities as of 18 Nov 2026, 14:30 UTC.
How many biotech are in this ranking?
24 are ranked by total liabilities.
What are these biotech worth together?
The 24 biotech ranked by total liabilities have a combined market value of NOK 8.21T as of 18 Nov 2026, 14:30 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.